뉴캐슬병 백신 시장 규모는 2024년에는 2억 8,927만 달러로 평가되었고 2026-2032년에 걸쳐 CAGR 3.20%를 나타내, 2032년에는 3억 7,216만 달러에 달할 것으로 예측되고 있습니다.
뉴캐슬병은 조류 파라믹소바이러스 1형(APMV-1)에 의해 유발되는 조류의 심각한 바이러스성 질환입니다. 가금류에 감염되어 특히 암탉이 감염되기 쉽습니다.이 바이러스는 배설물 경로로 감염됩니다.
미국 국립의료도서관에 의하면, 생후 2-3주령의 시판 튀르키예에 뉴캐슬병 바이러스(NDV) 생백신을 분무 접종했을 경우, 적혈구 응집 저해 검사로 검출되는 것 같은 높은 혈청 항체치나 지속적인 혈청 항체치는 별로 볼 수 없습니다. 튀르키예는 접종 후 2주째에 안비강 또는 에어로졸 경로로 도전했을 경우 감염과 임상 질환에 대해 충분한 저항성을 나타내었고, 6주째에 챌린지하면 임상 질환에 대해 저항성을 보였으나 백신 접종 후 10주까지 방어 수준은 저하되었습니다.
NDV가 만연하는 환경에서 사육되는 개발기 튀르키예가 NDV 자연 감염으로부터 완전히 보호되기 위해서는 2회 이상의 NDV 스프레이 백신 접종이 필요할 가능성이 시사되었습니다.
조류의 심각한 호흡 곤란과 신경 장애의 발생률 증가가 뉴캐슬병 백신 시장의 대폭적인 확대에 기여하고 있습니다. 시장 확대의 원동력이 될 것으로 예측됩니다. 뉴캐슬병 백신 시장은 사람들의 건강 유지의 이점에 대한 의식이 높아지고, 소비자 사이에서 질 높은 헬스케어 서비스에 대한 수요가 높아짐에 따라 확대되고 있습니다.
세계의 뉴캐슬병 백신 시장을 형성하는 주요 시장 역학은 다음과 같습니다.
주요 시장 성장 촉진요인
질병의 유행 : 가금 집단에서 뉴캐슬병(ND)의 존재는 뉴캐슬병 백신 산업의 주요 촉진요인입니다.
가금류 산업의 성장 : 육류 및 계란과 같은 닭고기 제품에 대한 세계 수요 증가에 힘입어 가금류 산업의 확대는 뉴캐슬병 백신 시장의 견인 역할을 하고 있습니다.
환경과 바이오 보안에 대한 우려 : 바이오 보안과 질병 발생이 환경에 미치는 영향에 대한 우려 증가는 예방 접종과 같은 예방 수단의 사용을 촉진하고 있습니다.
질병 발생 : 뉴캐슬병 발생은 특히 가금 생산 지역에서 예방 접종의 강화로 이어지고 뉴캐슬병 백신 시장 수요를 창출합니다.
주요 이슈
비용면에서의 제약 : 뉴캐슬병 백신은 높은 비용이기 때문에 특히 자금력이 부족한 소규모 양계 농업 종사자에서는 도입의 방해가 됩니다.경제적인 백신 제제를 개발해, 비용대 효과가 있는 예방접종 방법을 채용하는 것은 특히 저소득국가에서 널리 받아들여지고 질병을 컨트롤하기 위해서.
바이오 보안 의식의 향상 : 뉴캐슬병의 발생이 보다 일반적이고 대규모가 됨에 따라 농업 종사자들은 자신의 무리를 지키기 위한 바이오 보안 대책의 중요성을 인식하고 있습니다.
신형 균주의 출현 : 뉴캐슬병 바이러스는 항상 돌연변이되고 있으며, 보다 공격적인 신형 균주가 출현하고 있습니다.
백신에 대한 접근은 제한되어 있습니다. 뉴캐슬병 백신 등 동물용 백신에 대한 액세스가 제한된 빈곤국도 있습니다.
주요 동향
닭고기 제품에 대한 수요 증가 : 닭고기와 계란에 대한 세계 인구의 식욕이 확대됨에 따라 닭고기 생산이 증가하고 있습니다.
뉴캐슬병의 경제적 영향에 대한 지식 증가 : 가금류 업체는 뉴캐슬병이 초래하는 경제적 손실에 대해 더 강하게 의식하게 되었습니다. 여기에는 조류 사망률, 계란 생산량 감소, 무역 제한 등이 포함됩니다. 예방 접종은 이러한 손실을 방지하는 비용 효율적인 방법으로 간주됩니다.
예방접종 기술의 진보 : 보다 효과적이고 내열성이 높은 뉴캐슬병 백신의 연구개발이 진행되고 있습니다. 이는 백신의 보관 및 유통을 용이하게 하기 때문에 냉장 설비에 대한 접근이 제한된 지역에서 특히 중요합니다.
정부 법률 및 예방접종 프로그램 : 많은 정부가 닭 뉴캐슬병에 대한 의무적 백신접종 프로그램을 채택하고 있습니다. 이것은 질병의 확산을 억제하는 동시에 가금류 사업을 보호하는 데 도움이 됩니다.
Newcastle Disease Vaccine Market size was valued at USD 289.27 Million in 2024 and is projected to reach USD 372.16 Million by 2032, growing at a CAGR of 3.20% from 2026 to 2032.
Newcastle disease is a severe viral sickness in birds caused by avian paramyxovirus type 1 (APMV-1). It is very contagious and can spread too many domestic birds, including chickens and turkeys, with hens being especially vulnerable. The virus is spread by the fecal-oral route, which means that birds become infected after consuming contaminated droppings, food, drink, or equipment that has come into contact with sick birds.
According to National Library of Medicine, Commercial market turkeys spray-vaccinated at 2 to 3 weeks of age with live Newcastle disease virus (NDV) vaccine did not often generate high or persistent serum antibody levels as detected by the hemagglutination-inhibition test. Vaccinated turkeys demonstrated adequate resistance to infection and clinical disease when challenged by the oculonasal or aerosol route at 2 weeks post-vaccination, and they resisted clinical disease when challenged at 6 weeks, but the level of protection decreased by 10 weeks post-vaccination.
It is proposed that market turkeys raised in an NDV-enzootic environment may require two or more NDV spray vaccinations during their developing phase in order to be fully protected against natural NDV infection.
The increasing incidence of severe respiratory distress and nervous difficulties in birds contributes to the huge expansion of the Newcastle Disease Vaccine Market. Expanding outbreaks of the disease, expanding demand for livestock for food, and continuous research to produce a treatment for this disease are expected to drive market expansion. The Newcastle Disease Vaccine Market is thriving as people become more aware of the benefits of maintaining good health, resulting in a greater demand for high-quality healthcare services among consumers.
The key market dynamics that are shaping the global Newcastle disease vaccine market include:
Key Market Drivers:
Disease Prevalence: The presence of Newcastle disease (ND) in poultry populations is a major driver of the Newcastle disease vaccine industry. As ND continues to affect poultry farms around the world, there is a great demand for effective vaccines to prevent the disease from spreading.
Growth of the Poultry Industry: The expansion of the poultry industry, fueled by rising global demand for chicken products such as meat and eggs, helps to drive the Newcastle disease vaccine market. As chicken production increases and spreads into new areas, the necessity for comprehensive immunization programs becomes increasingly pressing.
Environmental and Biosecurity Concerns: Growing concern about biosecurity and the environmental impact of disease outbreaks is driving the use of preventive measures like immunization. Proactive steps to avoid Newcastle disease can save the environment while also ensuring the long-term viability of chicken production systems.
Disease Outbreaks: Newcastle disease outbreaks, particularly in poultry-producing regions, lead to intensified immunization efforts and generate market demand for Newcastle disease vaccines. Outbreaks can cause large economic losses for poultry producers, highlighting the significance of effective vaccination efforts.
Key Challenges:
Cost Constraints: The high cost of Newcastle disease vaccines can deter adoption, especially among small-scale chicken breeders with limited financial resources. Developing economical vaccine formulations and adopting cost-effective immunization procedures is critical for ensuring widespread acceptance and disease control particularly in low-income nations.
Increased Biosecurity Awareness: As Newcastle disease outbreaks become more common and extensive, farmers recognize the significance of biosecurity measures to protect their flocks. Vaccination is a critical component of biosecurity measures, which is boosting the demand for Newcastle disease vaccine.
Emergence of New Strains: The Newcastle disease virus is constantly mutating, with new and more aggressive strains appearing. These novel strains may render current vaccines ineffective, prompting the creation of new and improved vaccines. This can be a long and costly process.
Limited Access to Vaccines: Some impoverished countries have limited access to veterinary vaccines, such as Newcastle disease vaccines. This is due to a variety of issues, including inadequate infrastructure, money, and awareness. Farmers in these nations have fewer options for protecting their animals from Newcastle disease.
Key Trends:
Rising Demand for Chicken Products: The global population's expanding appetite for poultry meat and eggs has resulted in increased poultry production. This increases the need for immunization to protect birds from Newcastle disease outbreaks, which may kill chicks and result in considerable economic losses.
Increasing Knowledge of Newcastle Disease's Economic Impact: Poultry growers are becoming more conscious of the financial losses caused by Newcastle disease. This includes avian mortality, reduced egg output, and trade restrictions. Vaccination is viewed as a cost-effective method of preventing these losses.
Advances in Vaccination Technology: Research and development are underway to build more effective and thermostable Newcastle disease vaccines. This is especially significant in areas with limited refrigeration access, as it facilitates vaccine storage and distribution.
Government Laws and Immunization Programs: Many governments have adopted mandatory vaccination programs against Newcastle disease in chicken. This helps to control disease spread while also protecting the poultry business.
Here is a more detailed regional analysis of the global Newcastle disease vaccine market:
North America:
The Newcastle disease vaccine market, owing to a robust chicken sector and high demand for poultry products, including meat and eggs. The region's chicken industry is well-established, but Newcastle disease poses ongoing challenges needing stringent preventive measures such as immunization. This need emphasizes the importance of Newcastle disease vaccines in protecting the region's poultry stock and assuring the continuation of its thriving poultry market.
Furthermore, North America's unwavering dedication to sustainable agriculture techniques and animal welfare encourages the use of Newcastle disease vaccines. Prioritizing poultry health and well-being demonstrates the region's commitment to sustaining high food safety and animal care standards, which resonates positively with both consumers and industry stakeholders.
North America's dominant market position not only represents its enormous contribution to the global Newcastle disease vaccine market, but also demonstrates its unwavering commitment to safeguarding the poultry industry's viability and resilience in the face of evolving disease threats.
Asia Pacific:
The Asia-Pacific region is expected to lead the Newcastle disease vaccine market, as it is home to some of the world's top poultry producers, including China, India, and Indonesia. Here, rising demand for poultry products, fueled by population growth and changing dietary habits, drives the need to protect poultry flocks from Newcastle disease outbreaks. As a result, there is a significant increase in demand for vaccines, emphasizing the importance of preventive measures in supporting the region's thriving poultry sector.
Furthermore, the Asia-Pacific area is experiencing tremendous development in the poultry business, as well as increased knowledge of biosecurity regulations. This double momentum not only strengthens the Newcastle disease vaccine market but also demonstrates the region's proactive approach to disease prevention in chicken production. These factors firmly position Asia-Pacific as a key catalyst for Newcastle disease vaccine market growth, demonstrating its critical role in maintaining the global poultry industry's resilience in the face of changing challenges.
Europe:
The European market is primed to emerge as a serious competitor, boosted by proactive government programs that assist research and development efforts, particularly in the field of Newcastle disease vaccines. With significant investments in improving veterinary science and tight regulatory frameworks, the region creates an atmosphere conducive to innovation in animal health solutions.
Furthermore, Europe's significant advancements in animal husbandry procedures strengthen its position in the Newcastle disease vaccine market. By embracing innovative techniques and technology aimed at improving animal welfare and disease prevention, the region demonstrates its commitment to upholding high animal health and food safety standards. This combination of government funding, scientific excellence, and modern husbandry techniques puts Europe as a major player set to make great advances in the international Newcastle disease vaccine market.
The Global Newcastle Disease Vaccine Market is segmented on the basis of Vaccine Type, Species, And Geography.
Based on Vaccine Type, the market is divided into Live Attenuated, Inactivated and Thermostable. The Live Attenuated Vaccines (LAV) segment dominated the market in 2022 and is expected to have the highest compound annual growth rate (CAGR) over the forecast period. LAVs have remained popular among poultry breeders due to their effectiveness, low cost, and potential to provide long-term immunity. These vaccines have demonstrated efficacy against many strains of Newcastle disease viruses and provide broad-spectrum protection.
Based on Species, the Newcastle disease vaccine market is segmented Chicken, Duck and Goose. The chicken sector grabbed the biggest market share and is expected to retain a significant compound annual growth rate (CAGR) over the projection period. Newcastle Disease Virus (NDV) is a major threat to the poultry industry, causing significant economic losses. As a result, the demand for Newcastle Disease Vaccines remains high among chicken farmers, making this segment the most profitable in the market.
The "Global Newcastle disease vaccine Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Merial, QYH Biotech, CEVA, Yebio, Ringpu (Tianjin) Bio-Pharmacy Co. Ltd,Bayer AG, Hipra, Anicon Labor GmbH, Chengdu Tech-bank Biological Products Co. Ltd., Ringpu Bio-Technology Co. Ltd., MSD Animal Health, Nisseiken Co., Harbin Veterinary Research Institute, Merck Animal Health, ChengDu Tecbond, DHN, Zoetis, Elanco (Lohmann), CAVAC, Vaksindo, FATRO. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.
Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.